News
Category: DIAN-TU Announcement
The Knight Family DIAN-TU-003 Amyloid Removal Trial
MEMO DATE: 15 April 2024 TO: DIAN-TU-001 Gantenerumab Open Label Extension Participants FROM: Dr. Randall Bateman, Director, Knight Family DIAN-TU...
The Knight Family DIAN-TU Primary Prevention Trial Announcement
The statement below is an update to the 20 December 2022 announcement by the Knight Family Dominantly Inherited Alzheimer Network...
The Knight Family DIAN-TU Amyloid Removal Trial
The statement below is an update to the 18 August 2023 announcement by the Knight Family Dominantly Inherited Alzheimer Network...
Update on the DIAN-TU-001 Trial with E2814 and Lecanemab (Eisai Co., Ltd)
The statement below is in response to Eisai’s 06 January 2023 announcement regarding the FDA’s accelerated approval of lecanemab for...
Update on the DIAN-TU-002 Primary Prevention Trial
20 December 2022 Update on the DIAN-TU-002 Primary Prevention Trial The statement below is an update to the 15 November...
Update on the DIAN-TU-001 Open Label Extension and DIAN-TU-002 Primary Prevention Trials with Gantenerumab (Roche/Genentech)
The statement below is in response to the 14 November 2022 announcement regarding the results from the GRADUATE I and...
Update on the DIAN-TU-001 Trial with E2814 and Investigational Lecanemab (Eisai Co., Ltd)
The statement below is in response to the 28 September 2022 announcement found on Eisai’s website. Eisai Co., Ltd. (Headquarters:...
New Alzheimer’s prevention trial in young people
$11.5 million commitment supports new Alzheimer’s prevention clinical trial
International Alzheimer’s clinical trial to test two drugs in combination